Literature DB >> 23912958

Impact of primary local treatment on the development of distant metastases or death through locoregional recurrence in young breast cancer patients.

E J Bantema-Joppe1, E R van den Heuvel, L de Munck, G H de Bock, W G J M Smit, P R Timmer, W V Dolsma, L Jansen, C P Schröder, S Siesling, J A Langendijk, J H Maduro.   

Abstract

In this study, we tested the hypothesis whether breast conserving therapy (BCT) compared with mastectomy is associated with a negative outcome in terms of distant metastases or death (DMD) and investigated the relation between locoregional recurrence (LRR) and DMD in young breast cancer (BC) patients. This study included a consecutive series of 536 patients ≤40 years of age at diagnosis with pathological T1N0-3M0 BC, treated between 1989 and 2005. A multistate survival model was used to evaluate the influences of local treatment and LRR on DMD, adjusted for potential prognostic factors. Patients were treated with mastectomy (N = 213) or BCT (N = 323). Median age at diagnosis was 36.3 years, with a median follow-up of 9.0 years. The 10-year actuarial cumulative incidence of DMD was 30.6 % after mastectomy and 26.3 % after BCT (P = 0.04). In total, 81 (15 %) LRRs were observed. After BCT, patients had a threefold higher risk of LRR than after mastectomy (HR 2.9; 95 % CI 1.6-5.3). Patients with LRR had a higher risk of DMD compared with patients without LRR (HR 5.5; 95 % CI 2.1-14.5). However, BCT was not negatively associated with DMD-after-LRR (HR 0.47; 95 % CI 0.2-1.1, BCT vs mastectomy). In conclusion, although LRR significantly affected DMD, the increased risk of LRR after BCT compared with mastectomy did not lead to a worse DMD outcome in BC patients ≤40 years of age.

Entities:  

Mesh:

Year:  2013        PMID: 23912958     DOI: 10.1007/s10549-013-2650-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy?

Authors:  Christine V Pestana; Chad A Livasy; Erin E Donahue; Brittany Neelands; Antoinette R Tan; Terry Sarantou; Lejla Hadzikadic-Gusic; Richard L White
Journal:  Ann Surg Oncol       Date:  2022-07-09       Impact factor: 4.339

2.  Risk factors for locoregional recurrence after postmastectomy radiotherapy in breast cancer patients with four or more positive axillary lymph nodes.

Authors:  Q Li; S Wu; J Zhou; J Sun; F Li; Q Lin; X Guan; H Lin; Z He
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

3.  Local Recurrence in Young Women with Breast Cancer: Breast Conserving Therapy vs. Mastectomy Alone.

Authors:  Dang Van Nguyen; Sang-Won Kim; Young-Taek Oh; O Kyu Noh; Yongsik Jung; Mison Chun; Dae Sung Yoon
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

4.  Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval.

Authors:  Annemieke Witteveen; Annemiek B G Kwast; Gabe S Sonke; Maarten J IJzerman; Sabine Siesling
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

5.  The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer.

Authors:  Cetin Ordu; Kandace McGuire; Gul Alco; Kezban Nur Pilanci; Ulkuhan I Koksal; Filiz Elbüken; Zeynep Erdogan; Filiz Agacayak; Serkan Ilgun; Dauren Sarsenov; Alper Öztürk; Şefik İğdem; Sait Okkan; Yeşim Eralp; Maktav Dincer; Vahit Ozmen
Journal:  Cureus       Date:  2016-06-07

6.  Treatment and long-term outcome of breast cancer in very young women: nationwide population-based study.

Authors:  L-J Chen; Y-J Chang; Y-J Chang
Journal:  BJS Open       Date:  2021-09-06

7.  Patterns and predictors of first and subsequent recurrence in women with early breast cancer.

Authors:  Y M Geurts; A Witteveen; R Bretveld; P M Poortmans; G S Sonke; L J A Strobbe; S Siesling
Journal:  Breast Cancer Res Treat       Date:  2017-07-04       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.